411 related articles for article (PubMed ID: 31749159)
1. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.
de Wijs LEM; Nguyen NT; Kunkeler ACM; Nijsten T; Damman J; Hijnen DJ
Br J Dermatol; 2020 Oct; 183(4):745-749. PubMed ID: 31749159
[TBL] [Abstract][Full Text] [Related]
2. Case report: Clinical and histopathological characteristics of psoriasiform erythema and
Ali K; Wu L; Qiu Y; Li M
Front Med (Lausanne); 2022; 9():932766. PubMed ID: 35966849
[TBL] [Abstract][Full Text] [Related]
3. Facial and neck erythema associated with dupilumab treatment: A systematic review.
Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort.
Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V
Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
6. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis.
Russo F; Rizzo A; Santi F; Lamberti A; Lazzeri L; Flori ML; Rubegni P
Int J Dermatol; 2022 Jun; 61(6):e204-e206. PubMed ID: 34480761
[No Abstract] [Full Text] [Related]
7. Dupilumab facial redness: histologic characterization on a series of four cases.
Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T
Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583
[TBL] [Abstract][Full Text] [Related]
8. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
9. Angioedema: A potential complication of dupilumab in atopic dermatitis.
Fritz AL; Lacy FA; Morrell DS
Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
[TBL] [Abstract][Full Text] [Related]
10. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ
Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810
[TBL] [Abstract][Full Text] [Related]
12. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
15. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis.
Bax CE; Khurana MC; Treat JR; Castelo-Soccio L; Rubin AI; McMahon PJ
Pediatr Dermatol; 2021 Mar; 38(2):390-394. PubMed ID: 33426747
[TBL] [Abstract][Full Text] [Related]
16. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
Hendricks AJ; Yosipovitch G; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
[No Abstract] [Full Text] [Related]
19. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
